Indication
Ekterly is indicated for symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults and adolescents aged 12 years and older.
Loading your page…
Loading your page…
Angioedemas, Hereditary
Marketing Authorisation Holder: Kalvista Pharmaceuticals (Ireland) Limited
EMA Authorisation: 17/09/2025
INN: sebetralstat
AI Drug & Interaction Analysis
Free account required
Ask Osler about Ekterly: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.